Ameriprise’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-314,024
| Closed | -$1.29M | – | 4045 |
|
|
2022
Q1 | $1.29M | Buy |
314,024
+6,457
| +2% | +$23.4K | ﹤0.01% | 3095 |
|
|
2021
Q4 | $1.1M | Buy |
307,567
+284,346
| +1,225% | +$994K | ﹤0.01% | 3220 |
|
|
2021
Q3 | $85K | Buy |
23,221
+4,167
| +22% | +$16.8K | ﹤0.01% | 3791 |
|
|
2021
Q2 | $83K | Buy |
19,054
+7,054
| +59% | +$28.7K | ﹤0.01% | 3837 |
|
|
2021
Q1 | $49K | Hold |
12,000
| – | – | ﹤0.01% | 3803 |
|
|
2020
Q4 | $48K | Sell |
12,000
-2,500
| -17% | -$8.09K | ﹤0.01% | 3726 |
|
|
2020
Q3 | $39K | Buy |
+14,500
| New | +$40.1K | ﹤0.01% | 3687 |
|
|
2014
Q4 | – | Sell |
-350
| Closed | -$1K | – | 4587 |
|
|
2014
Q3 | $1K | Sell |
350
-955
| -73% | -$2.08K | ﹤0.01% | 5614 |
|
|
2014
Q2 | $3K | Buy |
+1,305
| New | +$3.93K | ﹤0.01% | 5120 |
|
|
2013
Q4 | – | Sell |
-7,027
| Closed | -$29K | – | 5487 |
|
|
2013
Q3 | $29K | Hold |
7,027
| – | – | ﹤0.01% | 4159 |
|
|
2013
Q2 | $29K | Buy |
+7,027
| New | +$27.1K | ﹤0.01% | 4060 |
|
Other funds holding ATRS
Ameriprise's ATRS Position: Q2 2022 in Review
Ameriprise sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 314,024 shares — an estimated $1.29M sold.
Ameriprise first reported a position in ATRS in Q2 2013 and held it in 11 quarters. The position peaked at $1.29M in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Ameriprise reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Ameriprise sold 314,024 Antares Pharma, Inc. shares in Q2 2022, an estimated $1.29M.
- Ameriprise first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 11 quarters.
- Ameriprise's Antares Pharma, Inc. position peaked at $1.29M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.